Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,057 | 262 | 2,765 |
| Samples | 699 | 62 | 628 |
| Peptides | 606 | 59 | 549 |
Function
STON1-GTF2A1L · STON1-GTF2A1L readthrough
STON1-GTF2A1L mRNAs are infrequent but naturally occurring read-through products of the neighboring STON1 and GTF2A1L genes. These transcripts encode fusion proteins composed of the vast majority of each of the individual elements, stonin 1 and general transcription factor IIA, 1-like. Alternative splicing results in multiple transcript variants. The significance of these read-through variants and the function of the resulting protein products have not yet been determined. [provided by RefSeq, Oct 2010].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 558 amino-acid changes on canonical ENST00000402114 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in STON1-GTF2A1L · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in STON1-GTF2A1L – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 5/210 2% | 133/1899 7% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 46/810 6% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 25/612 4% |
| Non-Small Cell Lung Carcinoma | 14/304 5% | 47/1390 3% |
| Other Solid Cancers | 2/94 2% | 42/1515 3% |
| Colorectal Carcinoma | 5/143 4% | 80/3239 2% |
| Bladder Carcinoma | 0/58 0% | 21/956 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 15/752 2% |
| Gastric Carcinoma | 1/74 1% | 32/1809 2% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Head and Neck Carcinoma | 1/85 1% | 20/1574 1% |
| Neuroendocrine Tumour | 5/154 3% | 4/577 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 24/2550 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Mesothelioma | 1/62 2% | 1/165 1% |
| Other Sarcomas | 0/69 0% | 6/699 1% |
| Meningioma | 0/3 0% | 2/252 1% |
| Biliary Tract Carcinoma | 0/54 0% | 7/950 1% |
| Glioma | 1/52 2% | 14/2127 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Breast Carcinoma | 4/144 3% | 18/3264 1% |
| Pancreatic Carcinoma | 0/89 0% | 11/1611 1% |
| Hepatocellular Carcinoma | 1/46 2% | 13/2210 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 9/1592 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
Mutation Distribution
Where STON1-GTF2A1L is mutated · all tissues, split by cell line vs tissue
How many mutations in STON1-GTF2A1L were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 41 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,057 mutations in STON1-GTF2A1L
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|